Combination therapy for advanced hormone-positive breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new combination of two study drugs (JSKN016 and D-0502) for people with a common type of advanced breast cancer (HR-positive, HER2-negative) that has grown after standard hormonal and CDK4/6 inhibitor treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your breast cancer must be HR-positive (estrogen or progesterone receptor positive) and HER2-negative, and it must be locally advanced or metastatic (spread beyond the breast).
- You must have tried a type of targeted therapy called a CDK4/6 inhibitor combined with hormone therapy, and your cancer must have gotten worse on that treatment.
- You need to have at least one measurable tumor outside the brain, and you should be able to carry on normal activities with minimal limitations (ECOG 0-1).
- You must be postmenopausal, or if premenopausal, you must be willing to receive medication to suppress ovarian function.
- You must not have untreated or active brain metastases, and cannot have had certain prior treatments or conditions like active lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two targeted medicines for people with a certain type of advanced breast cancer that has grown despite hormone therapy. The medicines may help shrink tumors and slow the cancer's growth.
This trial tests a new combination drug (JSKN016) for people with HER2-negative breast cancer that has spread or cannot be removed. It is for those who have not yet had advanced-stage treatment (except hormone therapy) and may offer a new option.
This study tests whether combining two new drugs (AK146D1 and AK112) can help people with advanced breast cancer that is HER2-negative (a type that doesn't have too much of a specific growth protein). The goal is to see if this combination can shrink tumors and improve survival.
This trial compares a new targeted therapy (JSKN003) against Kadcyla (T-DM1) for people with HER2-positive breast cancer that has advanced or spread. Both drugs work by attaching a chemotherapy directly to HER2-positive cancer cells, and the study aims to see if the new drug works better or has fewer side effects.
This trial tests a new drug combined with other anti-cancer drugs for advanced breast cancer. The goal is to see if the combination can shrink tumors and help people live longer, and if it is safe.
This trial tests a new drug, JSKN016HC, in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the tumor.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.